drugset

drugset / Trial / NCT00142181

Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

NCT00142181 ↗

Phase 2 Completed 27 enrolled Dana-Farber Cancer Institute Arizona Oncology Associates · collab Bayer · collab Beth Israel Deaconess Medical Center · collab Brigham and Women's Hospital · collab Massachusetts General Hospital · collab Northwestern University · collab University of California, Los Angeles · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H antibody in the treatment of lymphoplasmacytic lymphoma.

Timeline

Start: 2003-03
Primary completion: 2005-10
Completion: 2008-06

Publications

Results Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14;118(2):276-81. doi: 10.1182/blood-2011-02-338558. Epub 2011 May 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alemtuzumab	Monoclonal antibody	30 mg	Intravenous

Indications